No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

57 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Mouth Care Regimes During Radiotherapy

NCT00138827Phase 4Completed50 enrolled

Subcutaneous Amifostine Safety Study

NCT00158041Phase 4Completed452 enrolled

Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer

NCT00198263Phase 4Completed95 enrolled

INEC Study: Immuno-modulating Enteral Nutrition in Cancer

NCT00333099Phase 4Completed250 enrolled

Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking

NCT00365508Phase 4Completed642 enrolled

View all 57 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Efficacy and safety of atezolizumab compared to docetaxel in non-small cell lung cancer patients regardless of PD-L1 status: a systematic review and meta-analysis.

Li Ximing, Zhao Hai, Cui Yonghong · Chin Clin Oncol · 2025

PMID: 41208418Meta-Analysis

A Comparison Between Intravesical Gemcitabine Plus Docetaxel and Intravesical Bacillus Calmette-Guérin in the Treatment of Nonmuscle Invasive Naive Urinary Bladder Cancer: A Systematic Review and Meta-analysis of Oncological Outcomes.

Tripathy Rachana, Kumar Lalit, Agarwal Sakshi et al. · Urology · 2025

PMID: 39798618Meta-Analysis

Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review.

Ventura Ignacio, Salcedo Nerea Pinilla, Pérez-Bermejo Marcelino et al. · Int J Mol Sci · 2025

PMID: 40076535Meta-AnalysisFull text (PMC)

Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: a meta-analysis.

Wu Jie, Wang Zhiqiang, Fu Yi · BMC Womens Health · 2025

PMID: 40055784Meta-AnalysisFull text (PMC)

Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis.

Syed Azka, Raza Hasan, Khaskheli Hameer Khan et al. · BMC Cancer · 2025

PMID: 40660223Meta-AnalysisFull text (PMC)

Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC.

Castro Elena, Wang Di, Walsh Sarah et al. · Future Oncol · 2025

PMID: 40045559Meta-AnalysisFull text (PMC)

Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis.

Zhang Ying, Zhou Xiao, Xu Ran et al. · BMC Urol · 2025

PMID: 39865253Meta-AnalysisFull text (PMC)

Progression-free survival estimation of docetaxel-based second-line treatment for advanced non-small cell lung cancer: a pooled analysis from 18 randomized control trials.

N Chaithra, Jain Anisha, C Sahana et al. · Front Oncol · 2024

PMID: 38807763Meta-AnalysisFull text (PMC)

The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: A systematic review and pre-clinical study.

Low Kaan, Foulkes Paola, Hills Frank et al. · Cancer Med · 2024

PMID: 39315544Meta-AnalysisFull text (PMC)

Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?

Sanmamed Noelia, Gómez-Rivas Juan, Buchser David et al. · Clin Genitourin Cancer · 2024

PMID: 37599133Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Docetaxel (substance)
SNOMED CT: 386918005
UMLS CUI: C0246415
RxNorm CUI: 72962

Clinical Data

This intervention maps to 9 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.